32 Participants Needed

Rucaparib + Nivolumab for Biliary Tract Cancer

Recruiting at 2 trial locations
VS
Overseen ByVaibhav Sahai, MBBS, MS
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Michigan Rogel Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests if using rucaparib and nivolumab together can help patients with Biliary Tract Cancer live longer. Rucaparib stops cancer cells from repairing themselves, and nivolumab boosts the immune system to fight the cancer.

Who Is on the Research Team?

Vaibhav Sahai Profile | University of ...

Vaibhav Sahai, MBBS, MS

Principal Investigator

Rogel Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with advanced biliary tract cancer who've had platinum-based chemotherapy but can't have surgery or other curative treatments. They must be in good physical condition, not have certain other cancers or serious medical issues, and agree to use effective contraception.

Inclusion Criteria

I finished chemotherapy over 6 months ago before starting platinum-based treatment for advanced disease.
I have tissue samples from previous procedures stored.
I am fully active or can carry out light work.
See 8 more

Exclusion Criteria

I have an autoimmune disease that affects my organs or requires immunosuppressive therapy.
I have another active cancer besides non-melanoma skin cancer or cervical carcinoma in situ.
I do not have any current, uncontrolled infections.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Rucaparib 600 mg PO BID days 1-28 and Nivolumab 240 mg IV days 1 and 15

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to two years

What Are the Treatments Tested in This Trial?

Interventions

  • Nivolumab
  • Rucaparib
Trial Overview The study tests if rucaparib combined with nivolumab improves survival for patients after first-line platinum chemotherapy. It's for those whose disease hasn't worsened during initial treatment and who meet specific health criteria.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Rucaparib and NivolumabExperimental Treatment2 Interventions

Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:

🇺🇸
Approved in United States as Opdivo for:
🇪🇺
Approved in European Union as Opdivo for:
🇨🇦
Approved in Canada as Opdivo for:
🇨🇭
Approved in Switzerland as Opdivo for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Michigan Rogel Cancer Center

Lead Sponsor

Trials
303
Recruited
20,700+

Dana-Farber Cancer Institute

Collaborator

Trials
1,128
Recruited
382,000+

Vanderbilt University Medical Center

Collaborator

Trials
922
Recruited
939,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security